Cisplatin Neurotoxicity

Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir

“…An alternative therapeutic approach is to target an upstream phenomenon, that is, the generation of oxidative stress by oxaliplatin. Indeed, in 1990, Mollman et al observed that cisplatin-induced neuropathy is clinically indistinguishable from the neuropathy observed in patients with vitamin E deficiency (12). Since vitamin E is an antioxidant that maintains lipid-rich neural membranes, a molecule able to detoxify the ROS generated by oxaliplatin could prevent the drug's neurotoxicity (13).…”

Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy

“…Treatment, however, is associated with several side effects such as nephrotoxicity and neurotoxicity (Mollman, 1990). Although damage of kidney tubular epithelium cells can be avoided by forced diuresis, peripheral neurotoxicity remains a severe clinical problem and a major dose-limiting factor of cisplatin therapy (LoMonaco et al, 1992).…”

Interventions for preventing neuropathy caused by cisplatin and related compounds

“…It has been used since the early 1970s to treat several kinds of solid tumors, including lung, ovary, testis, bladder, head and neck, and endometrium (Mollman 1990;Prestayko 1979). Typical dosage regimes vary from 50 to 100 mg/m 2 given intravenously every three to four weeks, usually for about six cycles, based on clinical response and toxicity.…”

“…Alternative schedules include 20 mg/m 2 daily for 5 days, or 20 mg/m 2 given weekly for about six weeks. Cisplatin is known to be toxic to the nervous system (Mollman 1990;vander-Hoop 1990;Von Hoff 1979;Cavaletti 2004) and exhibits preferential uptake in the dorsal root ganglia and produces a dose-related large fibre sensory neuropathy (neuronopathy). The sensory neuropathy most often becomes evident after a cumulative cisplatin dose of at least 300 mg/m 2 , but occasional patients, especially those with risk factors, those with pre-existing neuropathy, and those with combination chemotherapy may develop symptoms after lower cumulative doses (Roelofs 1984;Windebank 1994).…”